Drug intelligence / Profile preview

RYZ811

Development stage: Unknown
Lead developer: RayzeBio
Modality: Peptides, Small Molecules
Administration: Parenteral

Overview

**RYZ811** is a diagnostic radiopharmaceutical agent consisting of a radionuclide-peptide complex that uses gallium-68 as the radioisotope. It is developed as an imaging agent for positron emission tomography (PET) to identify glypican-3 (GPC3) positive hepatocellular carcinoma (HCC) tumors. The agent binds to GPC3, a protein highly expressed on the surface of certain liver cancer cells, allowing for targeted PET imaging. RYZ811 is paired with RYZ801 (therapeutic agent) as part of a theranostic approach for unresectable HCC. RYZ811 is not intended for treatment but for diagnostic imaging only. The developer and originator are RayzeBio, in collaboration with PeptiDream[7][4][9][5].

Brand names: RYZ811RYZ-811RYZ 811
Other names: 68Ga-Ga-RYZ-GPC368Ga-GPC3 - Peptidream/RayzeBio

Targets

GPC3 (Glypican-3)

Beyond the preview

Go deeper on RYZ811.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RYZ811.

Explore the full profile